M
Moderna Therapeutics
Provides a real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease
At a glance
- Status
- Listed
- Listing
- IPO 2018
Open roles
Moderna Therapeutics in the Cambridge ecosystem
The Moderna Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later19 investors entered at this stage
- APArrowMark Partners
- HSHarvard Medical School
- INInvus
- BVBB Biotech Ventures
RA Capital Management- EDEDBI
- PIPictet
- JGJulius Baer Group
- MKMerck KGaA
Wellington Management
Sequoia- HUHarvard University
Alexion Pharmaceuticals- ASAstraZeneca
- CBChildren’s Hospital Boston
- AIAlexandria Venture Investments
Fidelity Investments- VIViking Global Investors
- AAAbu Dhabi Investment Authority
Source: Dealroom Talent Intelligence.
Alumni founders
Former Moderna Therapeutics employees who went on to found companies, sorted by Dealroom signal score.
LSLila SciencesEst. 2022
FBFortitude BiomedicinesEst. 2025
Jesse ChenUnited States
DBDash BioEst. 2024
Sébastien BalasFrance
Axel BouchonUnited StatesPatents
234 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Investments and acquisitions
Disclosed deals where Moderna Therapeutics was the backer or acquirer, 2014–2023. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.
5 deals across Moderna Therapeutics's capital deployment.
Where the deals concentrate by sector, stage, and decade.
Moderna Therapeutics's portfolio, mapped.
See Moderna Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.
Moderna cuts Ares loan rate, girds for $4B yearly spend through 2030
Moderna raises $2.6B convertible note as it pivots to cancer mRNA
Moderna to raise $2B in convertible notes after cancer vaccine rally


